We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 8.170+3.4%Dec 1 3:50 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: richardred8/23/2021 8:26:23 AM
1 Recommendation

Recommended By
Robert O

   of 6101
Trillium Therapeutics TRIL | Up 191.13%

Shares of Trillium Therapeutics ( TRIL) more than tripled early Monday after Pfizer said it would buy the cancer therapy specialist in a deal worth $2.26 billion.

Trillium's drug portfolio includes biologics treatments that "enhance the ability of patients’ innate immune system to detect and destroy cancer cells," Pfizer said.

Pfizer had first invested $25 million in Trillium in September 2020.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext